Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model

Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease with no decisive treatment. The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Morishita, Asahiro, Tadokoro, Tomoko, Fujihara, Shintaro, Iwama, Hisakazu, Oura, Kyoko, Fujita, Koji, Tani, Joji, Takuma, Kei, Nakahara, Mai, Shi, Tingting, Haba, Reiji, Okano, Keiichi, Nishiyama, Akira, Ono, Masafumi, Himoto, Takashi, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863244/
https://www.ncbi.nlm.nih.gov/pubmed/35192632
http://dx.doi.org/10.1371/journal.pone.0261310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863244/
https://www.ncbi.nlm.nih.gov/pubmed/35192632
http://dx.doi.org/10.1371/journal.pone.0261310

Ejemplares similares